M&A

Emergent BioSolutions Buys PaxVax for $270 Million
Emergent BioSolutions Buys PaxVax for $270 Million
BioSpace
M&A
Emergent BioSolutions
PaxVax
Flag link:
Boston Scientific inks $160m deal for peripheral stent maker Veniti
Boston Scientific inks $160m deal for peripheral stent maker Veniti
Mass Device
Boston Scientific
M&A
devices
Veniti
Flag link:
Allergan preludes major selloffs with $650M Almirall dermatology sale
Allergan preludes major selloffs with $650M Almirall dermatology sale
Fierce Pharma
Allergan
dermatology
Almirall
M&A
Flag link:
Takeda announces new series of non-core-asset sales
Takeda announces new series of non-core-asset sales
GoinPharma
Takeda
Shire
M&A
Flag link:
California Insurance Commissioner Asks DOJ To Block CVS-Aetna Merger
California Insurance Commissioner Asks DOJ To Block CVS-Aetna Merger
Forbes
insurers
M&A
DOJ
CVS Health
Aetna
California
Flag link:
Bayer sells prescription dermatology brands to Denmark's Leo Pharma
Bayer sells prescription dermatology brands to Denmark's Leo Pharma
Reuters
Bayer
LEO Pharma
dermatology
M&A
Flag link:
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Endpoints
Takeda
Shire
M&A
Flag link:
First rumors about Gilead – Vertex or Gilead – Pfizer merger start circulating
First rumors about Gilead – Vertex or Gilead – Pfizer merger start circulating
GoinPharma
Gilead Sciences
Vertex Pharmaceuticals
Pfizer
M&A
Flag link:
Would AbbVie’s top execs really pull the trigger on a $30B M&A deal? Why, yes, actually
Would AbbVie’s top execs really pull the trigger on a $30B M&A deal? Why, yes, actually
Endpoints
AbbVie
M&A
Flag link:
Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
Sangamo Bags TxCell, and a Next-Gen Cell Therapy Tech, for $84M
Xconomy
Sangamo BioSciences
M&A
TxCell
autoimmune disease
cell therapy
Flag link:
Astellas exploring selling Europe assets for $500m
Astellas exploring selling Europe assets for $500m
GoinPharma
Astellas
Europe
M&A
Flag link:
Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock
Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock
Endpoints
PTC Therapeutics
gene therapy
M&A
Agilis
Flag link:
Gilead’s Kite bags option to buy gamma delta startup Gadeta
Gilead’s Kite bags option to buy gamma delta startup Gadeta
Fierce Biotech
Gilead Sciences
Kite Pharma
Gadeta
T-cell receptors
M&A
Flag link:
Publicis Health acquires Payer Sciences
Publicis Health acquires Payer Sciences
Medical Marketing and Media
Publicis Health
M&A
Payer Sciences
payers
Flag link:
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Amgen
biosimilars
Neulasta
Alexion
M&A
Flag link:
CVS-Aetna merger may get the green light
CVS-Aetna merger may get the green light
Axios
CVS Health
Aetna
insurers
M&A
Flag link:
AngioDynamics CEO Clemmer is on the M&A trail
AngioDynamics CEO Clemmer is on the M&A trail
Mass Device
AngioDynamics
Pharma CEOs
Jim Clemmer
M&A
devices
Flag link:
BioCryst nixes merger, sending Idera stock down
BioCryst nixes merger, sending Idera stock down
Biopharma Dive
Idera
Biocryst
M&A
Flag link:
Gerresheimer to acquire Sensile Medical and its drug-delivery tech
Gerresheimer to acquire Sensile Medical and its drug-delivery tech
Mass Device
devices
Gerresheimer
Sensile Medical
M&A
Flag link:
4 Things You Need to Know About Pfizer's Restructuring Plans
4 Things You Need to Know About Pfizer's Restructuring Plans
Motley Fool
Pfizer
restructuring
M&A
consumer health
reorganization
Flag link:

Pages